TherapeuticsMD Inc (NASDAQ:TXMD) – Equities researchers at Oppenheimer lifted their Q2 2019 EPS estimates for TherapeuticsMD in a research note issued to investors on Tuesday, June 11th. Oppenheimer analyst J. Olson now forecasts that the company will post earnings per share of ($0.14) for the quarter, up from their previous estimate of ($0.16). Oppenheimer currently has a “Outperform” rating and a $10.00 target price on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s Q3 2019 earnings at ($0.16) EPS, Q4 2019 earnings at ($0.09) EPS, FY2019 earnings at ($0.55) EPS and FY2023 earnings at $1.20 EPS.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.01. TherapeuticsMD had a negative net margin of 907.71% and a negative return on equity of 159.71%. The business had revenue of $3.95 million for the quarter, compared to analyst estimates of $5.96 million. During the same quarter in the prior year, the business earned ($0.11) EPS. TherapeuticsMD’s quarterly revenue was up 4.8% on a year-over-year basis.
Shares of NASDAQ:TXMD opened at $2.44 on Friday. TherapeuticsMD has a 12-month low of $2.21 and a 12-month high of $7.42. The company has a market cap of $593.41 million, a price-to-earnings ratio of -4.14 and a beta of 2.14. The company has a current ratio of 3.39, a quick ratio of 3.28 and a debt-to-equity ratio of 1.26.
Large investors have recently made changes to their positions in the business. Private Ocean LLC acquired a new position in shares of TherapeuticsMD during the 1st quarter worth approximately $37,000. Advisor Group Inc. lifted its holdings in shares of TherapeuticsMD by 163.4% during the 1st quarter. Advisor Group Inc. now owns 8,060 shares of the company’s stock worth $38,000 after acquiring an additional 5,000 shares during the period. Menta Capital LLC bought a new stake in shares of TherapeuticsMD during the 1st quarter worth approximately $56,000. Weiss Multi Strategy Advisers LLC bought a new stake in shares of TherapeuticsMD during the 4th quarter worth approximately $57,000. Finally, Creative Planning bought a new stake in shares of TherapeuticsMD during the 4th quarter worth approximately $63,000. Hedge funds and other institutional investors own 78.93% of the company’s stock.
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Featured Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.